Biotech IPOs off to better start in 2017

Rebound from a weaker 2016 performance, plus a newly minted Trump administration and investor optimism should support a more robust IPO market in 2017, but doubts remain.

By Jacob Bell • Feb. 3, 2017

Astellas inks biomarker deal to pinpoint Xtandi patients

GenomeDx Biosciences' genome profiling tech will help identify the patients who are most likely to respond to Astellas' drug.

By Suzanne Elvidge • Feb. 3, 2017

Cytokinetics pulls in Royalty Pharma to secure $100M

The late-stage biotech says the deal will give it needed cash to pump into a Phase 3 trial of its heart failure drug candidate.

By Judy Packer-Tursman • Feb. 2, 2017

Novo Nordisk plans $145M investment in new UK research center

Amid the uncertainty of Brexit, Novo Nordisk's partnership with the University of Oxford is a dose of good news for British science.

By Suzanne Elvidge • Feb. 2, 2017

Biogen nixes licensing deal for autoimmune drug

The Cambridge biotech had paid Mitsubishi Tanabe $60 million to gain access to the drug a year and a half ago, but hopes for a Gilenya competitor didn't pan out. 

By Judy Packer-Tursman • Feb. 1, 2017

Takeda bolsters cancer pipeline with Exelixis deal

The Japanese pharma already kicked off 2017 with a $5.2 billion deal for Ariad Pharma and its blood cancer drug — part of a broader effort to build out a more competitive portfolio in oncology. 

By Suzanne Elvidge • Feb. 1, 2017

Mallinckrodt unloads spinal drug unit

The deal, worth up to $357 million, continues the U.K.-based biopharma's work to refine its specialty drug pipeline.

By Jacob Bell • Jan. 31, 2017

Calithera shares jump on Incyte deal

The companies combine oncology expertise towards a potential combination therapy approach.

By Suzanne Elvidge • Jan. 31, 2017

Adocia falls after Lilly exit

Adocia is seeking a new partner after the big pharma's surprise withdrawal led to a sharp drop in the company's stock. 

By Suzanne Elvidge • Jan. 30, 2017

Prescribed Reading: J&J closes $30B deal, FDA talks regen med

J&J finally closes the deal with Actelion, despite poor data for Opsumit, while the FDA creates a new designation and Biogen looks to woo payers with data. 

By Lisa LaMotta • Jan. 27, 2017

Intrexon picks up struggling GenVec to build delivery tech

GenVec specializes in adenovirus gene delivery technology but has seen its stock stagnate over the past two years. 

By Ned Pagliarulo • Jan. 26, 2017

Regeneron drops $720M to buy New York HQ

The biotech has leased the space for years, but will now cement its presence in the state by buying the property outright. 

By Judy Packer-Tursman • Jan. 26, 2017

J&J seals $30B deal for Actelion

Under the deal, the Swiss biotech will spin out its R&D efforts into a new public company to be led by Actelion CEO Jean-Paul Clozel. 

By Ned Pagliarulo • Jan. 26, 2017

Prescribed Reading: A new era in pharma

Trump is in, Califf is out, Bristol-Myers foregoes any possible lead in lung cancer and the FDA made its mark. 

By Lisa LaMotta • Jan. 20, 2017

Cytori hooks Azaya, acquires delivery platform

Azaya's platform could deliver regenerative medicine for an aging population.

By Suzanne Elvidge • Jan. 20, 2017

Earnings preview: 7 biopharmas to watch

J&J, Novartis, Bristol-Myers, AbbVie and several notable biotechs will drive the first week of full-year earnings this January. 

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Jan. 19, 2017

Evotec creates fibrotic disease company through new partnership

The new, Toronto-based business will investigate novel molecules to treat tissue scarring in organs such as the liver, kidneys and lungs. 

By Jacob Bell • Jan. 19, 2017

Takeda and Ovid hook up in rare pediatric epilepsies

Big pharma shakes hands with small biotech in an equal shares agreement for a rare disease compound. 

By Suzanne Elvidge • Jan. 19, 2017

Merck KGaA inks big data deal

A deal with Silicon Valley unicorn Palantir should boost the German company's tech base for drug design, development and marketing.

By Suzanne Elvidge • Jan. 18, 2017

Lilly acquires CoLucid, strengthening neuro pipeline

Lilly will drop almost $1 billion to acquire the smaller player and its late-stage migraine drug.

By Jacob Bell • Jan. 18, 2017

JPM: Day 4 round-up

A host of biotechs, including Novavax and MannKind, brought the huge healthcare conference to a close on Thursday.

By Lisa LaMotta • Jan. 12, 2017

Takeda, Maverick join to drive T-cell therapeutics for cancer

The deal fits Takeda's broad strategy of strengthening its oncology offerings and expanding its footprint in the U.S.

By Judy Packer-Tursman • Jan. 12, 2017

Orchard Therapeutics partners with Dutch CMO PharmaCell to deliver gene therapy manufacturing

The partnership is expected to advance development of Orchard's rare disease investigational drugs.

By Suzanne Elvidge • Jan. 12, 2017

Bird Rock one step closer to acquisition by J&J

The approval of a Phase 1 trial for one of the small biopharma's drugs furthers the possibility of a takeover from Johnson & Johnson, which locked down acquisition rights earlier this year.

By Suzanne Elvidge • Jan. 12, 2017

JPM: Day 3 round-up

President-elect Trump threw a wrench into biotech's momentum with comments about drug pricing and other events at the last full day of J.P. Morgan. 

By Lisa LaMotta • Jan. 11, 2017